About Idorsia
Idorsia is a publicly listed company based in Allschwil (Switzerland) founded in 2017. Diversified drugs are developed and manufactured for multiple therapeutic areas. Its website idorsia.com draws about 39 thousand monthly visits. Idorsia offers products and services including Daridorexant, Aprocitentan, and Lucerastat. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Idorsia Pharmaceuticals Ltd.
Company details
Idorsia was established in 2017 and is headquartered in Allschwil, Switzerland. Operations center on research and development within the pharmaceutical sector, where diversified drugs are created for various therapeutic areas. Manufacturing processes support the production of these medications, with a focus on innovation across multiple health domains. The companys activities are conducted primarily in Europe, contributing to global therapeutic advancements through targeted RD initiatives.
- Headquarters Allschwil, Switzerland
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website idorsia.com
- Social LinkedIn X Facebook YouTube
- Legal Name Idorsia Ltd.
- Annual Revenue$278.27 M (USD)96.06as on Dec 31, 2025
- Net Profit-$140.91 M (USD)57.65as on Dec 31, 2025
- EBITDA-$143.26 M (USD)65.12as on Dec 31, 2025
- Latest Funding Round$81.64M (USD), Post-IPO
Oct 2025
- InvestorsUBS
& 3 more
Products & Services of Idorsia
Idorsia offers a comprehensive portfolio of products and services, including Daridorexant, Aprocitentan, and Lucerastat.
Treatment for insomnia in CNS disorders
Medication for hypertension management
Therapy for Fabry disease symptoms
Apps and channels of Idorsia
its YouTube channel Idorsia has 187 subscribers and 5 videos.
Videos from Idorsia
The most watched videos on Idorsia's YouTube channel, Idorsia (187 subscribers). Click a video to play it here.
More on Idorsia.
Funding Insights of Idorsia
- Total Rounds 4
- Last Round Post-IPO — $81.64M
- Investors Count 4
All 4 funding rounds of Idorsia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $81.64M | Post-IPO | – | – | |
| Jul 2021 | $655.44M | Post-IPO | – | – | – |
| Jun 2018 | $508.41M | Post-IPO | – | – | – |
| Feb 2018 | Post-IPO | – | – |
4 investors in total: 4 institutional.
Investors in Idorsia
Idorsia has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include UBS, J P Morgan and BB Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Financial services are provided globally by UBS for wealth management. | 1862 | ubs.com | Zurich, Switzerland | |
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
H.C. Wainwright & Co. is engaged in investment banking and advisory services. | hcwco.com | New York, United States |
Investor details for Idorsia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Idorsia
152 people are tracked at Idorsia (91 in leadership, 6 in board & advisors, 55 in team).
| Name | Role | Group |
|---|---|---|
Charlyse Herrmann | Senior Lab Head - Preformulation And Preclinical Galenics | Leadership |
Jürgen F. | Team Leader Data Management & Analytics, Director | Leadership |
Andrew C. Weiss | SVP & Head of Investor Relations & Corporate Communications | Leadership |
André C. Muller | EVP & CFO | Leadership |
Alberto Gimona | EVP & Head of Global Clinical Development | Leadership |
Simon Stamm | Associate Director, Principal Scientist | Leadership |
James Khoo | Associate Director UK Scientific Affairs Lead | Leadership |
Kerstin N. | Svp, Head Pharmacological Sciences | Leadership |
Meriem Bireche | Director QA (gmp/gdp,pv) / QP UK | Leadership |
Orestis Briasoulis | Vice President, Global Medical Affairs Lead | Leadership |
Martine Clozel | EVP & Chief Scientific Officer | Leadership |
Olivier Lambert | SVP & Head of Global Pharmaceutical Development & Quality Assurance | Leadership |
Jean-Paul Clozel | CEO | Leadership |
Alexis Asimakopoulos | Director, Analytics, Digitalisation & Process Improvement | Leadership |
Julian Müller | Director Of Finance And Commercial Excellence | Leadership |
Neil Burton | Director, Medical Information Eucan | Leadership |
Bastian Schneider | Vice President, Head Global Finance | Leadership |
Nina Erixon-Lindroth | Medical Director Nordics | Leadership |
Severine Litzler | Lab Head Preclinical In Vivo Toxicology | Leadership |
Antonio Crucitti | Vp, Head Of Global Drug Safety | Leadership |
132 more people are available in the full profile.
Complete people profiles for Idorsia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Idorsia
Idorsia is a publicly listed company on the SIX with ticker symbol IDIA in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2017
- Listed onSWX: IDIA
- Listed entityIdorsia Ltd.
- Exchange sectorHealth technology
- ISINCH0363463438
- Share price3.93 CHF (+1.03% on the day) · 2026-05-11
- Market capitalisation988,006,130.00 CHF
- EPS (diluted, trailing year)-0.54 CHF
- Volume (last session)277,633
- Analyst consensusNeutral
Financials of Idorsia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 220.6M CHF | -111.7M CHF | -113.6M CHF |
| 2024 | 112.5M CHF | -263.8M CHF | -325.6M CHF |
| 2023 | 152.4M CHF | -297.9M CHF | -524.0M CHF |
| 2022 | 97.1M CHF | -827.9M CHF | -783.1M CHF |
| 2021 | 35.4M CHF | -634.6M CHF | -595.0M CHF |
Detailed financial statements for Idorsia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Idorsia
4 dated milestones of Idorsia across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Idorsia is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $81.6M.
Web traffic of Idorsia
The website of Idorsia (idorsia.com) receives about 39.1K visits a month and ranks #913,080 among all websites worldwide, #1,094 in Biotechnology and Pharmaceuticals.
- Monthly visits39.1K
▲ 8.2% vs previous month
- Unique visitors11K
per month
- Global rank#913,080
among all websites
- Category rank#1,094
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.8
- Average visit21 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Idorsia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmaceutical-technology.com | 100% | #316,052 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Idorsia
Complete news archive for Idorsia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Idorsia
Idorsia was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Idorsia is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Annual revenue of Idorsia is $278.27M as on Dec 31, 2025.
Idorsia was established in 2017 and is headquartered in Allschwil, Switzerland. Operations center on research and development within the pharmaceutical sector, where diversified drugs are created for various therapeutic areas. Manufacturing processes support the production of these medications, with a focus on innovation across multiple health domains. The companys activities are conducted primarily in Europe, contributing to global therapeutic advancements through targeted RD initiatives.
Idorsia offers Daridorexant, Aprocitentan, and Lucerastat.
Yes, Idorsia is publicly traded on SIX under the ticker symbol IDIA.
Idorsia has 4 investors. Key investors include UBS, J P Morgan, BB Biotech, and H.C. Wainwright & Co.
Idorsia operates through Idorsia Pharmaceuticals Ltd.